Terapia antiplaquetaria en cáncer

  1. Torices, Alfonso 1
  2. Guerrero, Carmen 1
  1. 1 Universidad de Salamanca
    info

    Universidad de Salamanca

    Salamanca, España

    ROR https://ror.org/02f40zc51

Aldizkaria:
Farmajournal

ISSN: 2445-1355

Argitalpen urtea: 2021

Alea: 6

Zenbakia: 2

Orrialdeak: 63-73

Mota: Artikulua

DOI: 10.14201/FJ2021626373 DIALNET GOOGLE SCHOLAR lock_openSarbide irekia editor

Beste argitalpen batzuk: Farmajournal

Laburpena

Platelets contain granules with proangiogenic and antiangiogenic substances. In the tumor microenvironment, platelets interact with neoplastic cells, which release agonists that induce platelet activation and aggregation, as well as the secretion of proangiogenic factors that favor vascularization and tumor growth. In addition, platelets protect tumor cells from the immune system and promote the epithelial-mesenchymal transition, increasing their invasive capacity and favoring the appearance of metastasis. There are numerous studies showing the benefit of antiplatelet therapy in reducing metastases. In fact, the appearance of thromboembolisms during neoplastic development is a poor prognostic factor. In this work, we have compared the tumor progression of patients with colorectal cancer (CRC) treated with antiplatelet therapy with that of patients with the same neoplasm but without antiplatelet treatment. Our results showed that 90?% of the CRC patients treated with antiplatelet therapy did not develop metastases, compared to 59.8?% of the patients without such therapy. Statistical analysis of the data indicated a significant correlation between a high platelet count and the development of metastases. Therefore, antiplatelet therapy in cancer could be beneficial and complement conventional antineoplastic therapy.

Erreferentzia bibliografikoak

  • Cedervall J, Hamidi A, Olsson AK. Platelets, NETs and cancer. Thromb. Res. 2018; 164: S148-S152.
  • Contursi A, Grande R, Dovizio M, Bruno A, Fullone R, Patrignani P. Platelets in cancer development and diagnosis. Biochem. Soc. Trans. 2018; 46(6):1517-1527.
  • Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. P. Nat. Acad. Sci. USA. 1968; 61(1):46-52.
  • Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet ? granules and differentially released. Blood. 2008; 111(3):1227-1233.
  • Ivanov II, Apta BHR, Bonna AM, Harper MT. Platelet P-selectin triggers rapid surface exposure of tissue factor in monocytes. Sci. Rep. 2019; 9(1):13397-13406.
  • Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011; 20(5):576-590.
  • Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch. Intern. Med. 1964; 114(4):497-500.
  • Loomans-Kropp HA, Pinsky P, Cao Y, Chan AT, Umar A. Association of aspirin use with mortality risk among older adult participants in the prostate, lung, colorectal, and ovarian cancer screening trial. JAMA Netw. Open. 2019; 2(12): e1916729.
  • Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: a casual or causal relationship: revisited. Cancer Metast. Rev. 2014; 33(1):231-269.
  • Placke T, Örgel M, Schaller M, Jung G, Rammensee HG, Kopp HG et al. Platelet-derived mhc class i confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012; 72(2):440-448.
  • Serebruany VL, Kim MH, Cabrera-Fuentes HA, Lee K, Cho YR, Park K et al. Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. Thromb. Haemost. 2017; 117(5):934-939.
  • Stoiber D, Assinger A. Platelet-leukocyte interplay in cancer development and progression. Cells. 2020; 9(4):855.
  • Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019; 134(22):1912-1918.
  • Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl. J. Med. 2007; 357(20):2001-2015.
  • Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood. 2018; 131(16):1777-1789.
Datuen iturria: Dialnet